Fig. 8

Propranolol attenuated the effect of ATO on the lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in mouse cardiomyocytes and myocardial tissues. A Propranolol increased lncRNA Kcnq1ot1 expression in ATO-treated mouse cardiomyocytes. B Propranolol decreased miR-34a-5p expression in ATO-treated mouse cardiomyocytes. C Propranolol increased Sirt1 mRNA expression in ATO-treated mouse cardiomyocytes. D Propranolol increased Sirt1 protein expression in ATO-treated mouse cardiomyocytes. E Propranolol increased lncRNA Kcnq1ot1 expression in ATO-treated mouse myocardial tissues. F Propranolol decreased miR-34a-5p expression in ATO-treated mouse myocardial tissues. G Propranolol increased Sirt1 mRNA expression in ATO-treated mouse myocardial tissues. H Propranolol increased Sirt1 protein expression in ATO-treated mouse myocardial tissues. For A–H, one-way ANOVA F value = 10.17, 10.79, 25.16, 153.9, 9.598, 24.71, 12.15 and 4.356, respectively. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control group; ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. ATO group; n = 4–8